Table 3 Treatment Modalities by Breast Cancer Subtype
From: Breast Cancer Subtypes in Northern Thailand and Barriers to satisfactory survival outcomes
Luminal A-like N (%) | Luminal B-like N (%) | HER2 Enriched N (%) | Triple-Negative N (%) | P-Value | |
|---|---|---|---|---|---|
Surgery No Surgery Lumpectomy Mastectomy Total | 41 (4.5) 200 (22.0) 669 (73.5) 910 | 92 (8.0) 227 (19.8) 828 (72.2) 1,147 | 60 (9.5) 80 (12.6) 493 (77.9) 633 | 27 (5.8) 72 (15.6) 364 (78.6) 463 | < 0.001 |
Chemotherapy No Yes CMF1 FAC/FEC/AC2 AC-T3 Total | 268 (29.4) 642 (70.6) 56 (8.7) 461 (71.8) 125 (19.5) 910 | 307 (26.8) 840 (73.2) 30 (3.6) 610 (72.6) 200 (23.8) 1,147 | 100 (15.8) 533 (84.2) 20 (3.8) 371 (69.6) 142 (26.6) 633 | 72 (15.6) 391 (84.4) 25 (6.3) 286 (73.2) 80 (20.5) 463 | < 0.001 |
Radiation Therapy No Yes Total | 390 (42.9) 520 (57.1) 910 | 497 (43.3) 650 (56.7) 1,147 | 279 (44.1) 354 (55.9) 633 | 187 (40.4) 276 (59.6) 463 | 0.651 |
Hormonal Therapy No Yes Tamoxifen Aromatase Inhibitors Total | 67 (7.4) 843 (92.6) 541 (76.4) 167 (23.6) 910 | 100 (8.7) 1,047 (91.3) 624 (72.7) 234 (27.3) 1,147 | 592 (93.5) 41 (6.5) 32 (78.0) 9 (22.0) 633 | 453 (97.8) 10 (2.2) 10 (100.0) 0 (0.0) 463 | < 0.001 |
Anti-HER2 No Yes Total | 908 (99.8) 2 (0.2) 910 | 1,053 (91.8) 94 (8.2) 1,147 | 507 (80.1) 126 (19.9) 633 | 459 (99.1) 4 (0.9) 463 | < 0.001 |